Comparison between Continuous Saline Infusion and Intermittent Saline Flushing in preventing clot formation of Extracorporeal circuit in heparin free Hemodialysis - nil

Start Date25 Sep 2024

Sponsor / Collaborator-

CTRI/2024/08/072588 / Not yet recruitingNot Applicable

Heparin Dose Response Curve for Heparin Dose Determination During Paediatric Cardiopulmonary Bypass for Cardiac Surgery: A Prospective Randomised Control Study - Nil

Start Date25 Aug 2024

Sponsor / Collaborator-

CTRI/2024/07/071587 / Not yet recruitingNot ApplicableIIT

Comparative Evaluation Of Umbilical Cord Blood Serum Versus Low Dose Heparin Drops Versus Amniotic Membrane Grafting For Ocular Manifestations In Acute Stevens-Johnson Syndrome - nil

Start Date16 Aug 2024

Sponsor / Collaborator-

100 Clinical Results associated with Heparin Calcium

100 Translational Medicine associated with Heparin Calcium

100 Patents (Medical) associated with Heparin Calcium

63,359

Literatures (Medical) associated with Heparin Calcium

01 Apr 2025·DEN open

Establishment of a swine model of delayed bleeding after endoscopic procedure

Article

Author: Uehara, Shohei ; Sahara, Hisashi ; Tanaka, Akihito ; Sasaki, Fumisato ; Arima, Shiho ; Hashimoto, Shinichi ; Ido, Akio ; Maeda, Hidehito ; Kanmura, Shuji ; Hinokuchi, Makoto

Abstract:

Objectives:

Although delayed bleeding after endoscopic procedures has become a problem, currently, there are no appropriate animal models to validate methods for preventing it. This study aimed to establish an animal model of delayed bleeding after endoscopic procedures of the gastrointestinal tract.

Methods:

Activated coagulation time (ACT) was measured using blood samples drawn from a catheter inserted into the external jugular vein of swine (n = 7; age, 6 months; mean weight, 13.8 kg) under general anesthesia using the cut‐down method. An upper gastrointestinal endoscope was inserted orally, and 12 mucosal defects were created in the stomach by endoscopic mucosal resection using a ligating device. Hemostasis was confirmed at this time point. The heparin group (n = 4) received 50 units/kg of unfractionated heparin via a catheter; after confirming that the ACT was ≥200 s 10 min later, continuous heparin administration (50 units/kg/h) was started. After 24 h, an endoscope was inserted under general anesthesia to evaluate the blood volume in the stomach and the degree of blood adherence at the site of the mucosal defect.

Results:

Delayed bleeding was observed in three swine (75%) in the heparin‐treated group, who had a maximum ACT of >220 s before the start of continuous heparin administration. In the non‐treated group (n = 3), no prolonged ACT or delayed bleeding was observed at 24 h.

Conclusion:

An animal model of delayed bleeding after an endoscopic procedure in the gastrointestinal tract was established using a single dose of heparin and continuous heparin administration after confirming an ACT of 220 s.

01 Mar 2025·Journal of Medical Devices-Transactions of the ASME

Mechanical Viability and Functionality Assessment of a New Sutureless Endoluminal Microvascular Device: A Preliminary In Vivo Rabbit Study

Article

Author: Segura, Erica ; Bellemi, German ; Oyonate, Héctor ; Taylor, Brittany ; Fontdevila, Joan ; Descarrega, Jordi

Abstract:

Our group has developed a new nitinol endoluminal self-expandable device for microvascular anastomosis. It attaches to each vessel ending with opposite directed microspikes and reaches complete expansion at body temperature, using the nitinol shape memory capacity. The main purpose of this first in vivo trial is to evaluate the mechanical viability of the device and its immediate and early functionality. A recuperation study with seven New Zealand White rabbits was designed. A 1.96 mm outer diameter prototype of the new device was placed on the right femoral artery of each rabbit. Each anastomosis was reassessed on the seventh postoperative day to reevaluate the device function. The average anastomosis time with the new device was 18 min and 45 seg (±0.3 seg). It could be easily placed in all the cases with an average of 1.14 (1) complementary stitches needed to achieve a sealed anastomosis. Patency test was positive for all the cases on the immediate assessment. On the 1 week revision surgery, patency test was negative for the seven rabbits due to blood clot formation inside the device. The new device that we have developed is simple to use and shows correct immediate functionality. On the early assessment, the presence of a foreign body in the endoluminal space caused blood clot formation. We speculate that a heparin eluting version of the device could avoid thrombosis formation. We consider that the results obtained can be valuable for other endoluminal sutureless devices.

01 Jan 2025·INTERNATIONAL JOURNAL OF CARDIOLOGY

The efficacy of an intracoronary cocktail administration in preventing no-reflow during excimer laser coronary angioplasty in patients with in-stent restenosis: A pilot study. (ELCA- cocktail study)

Article

Author: Yang, Junjie ; Gao, Lei ; Guo, Jun ; Chen, Haiwei ; Wang, Qi ; Chen, Yundai ; He, Pan

BACKGROUND:

The no-reflow phenomenon is a significant complication during excimer laser coronary angioplasty (ELCA) procedures, which can lead to adverse outcomes. This study explores the efficacy of intracoronary administration of a cocktail solution comprising nitroglycerin, heparin, and verapamil on preventing no-reflow during ELCA in patients with in-stent restenosis (ISR).

METHODS:

This study included patients undergoing ELCA with contrast infusion for ISR. Based on whether receiving the intracoronary cocktail solution during ELCA, participants were divided into two groups: the cocktail (+) group and the cocktail (-) group. The primary endpoint was the incidence of no-reflow, which was defined as the cessation of blood flow into the distal coronary artery in the absence of a clear angiographic explanation for impairment of flow.

RESULTS:

A total of 54 lesions in 51 patients were included. The mean age of the study population was 61.8 ± 9.7 years, with 84.3 % male. Baseline clinical characteristics were well-balanced. The incidence of no-reflow was significantly lower in the cocktail (+) group compared to the cocktail (-) group (0 % vs. 17.9 %, P = 0.024). No cases of hypotension, major bleeding or coronary perforation in either group. Major adverse cardiac events (MACE) within 6-month were no significant difference between the groups (4.0 % vs. 3.8 %, P = 0.977).

CONCLUSIONS:

The pilot study suggests that intracoronary administration of a cocktail comprising heparin, nitroglycerin, and verapamil may reduce the incidence of no-reflow during ELCA in patients with ISR. However, given the limited sample size and the non-randomized design, these findings should be considered hypothesis-generating. Future validation needs to be confirmed through multicenter studies with larger sample sizes.

148

News (Medical) associated with Heparin Calcium

30 Oct 2024

·www.globenewswire.com

CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update

‒ Q3 2024 Net Revenue of $11.5 million ‒ ‒ Commercializing DefenCath with Four of Top Five US Dialysis Providers ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the third quarter and nine months ended September 30, 2024 and provided an update on its business. Recent Corporate Highlights: CorMedix today reports its first full quarter of DefenCath sales since commencing outpatient launch in July 2024. The Company reported net sales of $11.5 million for the third quarter, largely driven by successful implementation by an initial anchor customer, a mid-sized dialysis operator.During the third quarter, CorMedix announced commercial agreements with a large dialysis operator and two new mid-sized dialysis operators and now has commercial agreements providing access to roughly 60% of outpatient dialysis centers in the US. CorMedix is actively working with these customers to initiate DefenCath utilization in the 4th quarter of 2024.The Company has started to see pull-through of units to inpatient facilities as health systems begin to complete P&T reviews and provide patients access to DefenCath. CorMedix remains focused on building brand advocacy with key opinion leaders in this setting of care.Following FDA feedback, the Company is in the final stages of amending the clinical study protocol for Total Parenteral Nutrition, or TPN, and anticipates FDA submission by mid-November to align with our plans to operationalize the study in the first half of 2025. In addition, CorMedix remains on track with a real-world evidence study, the pediatric hemodialysis study, and the expanded access program for DefenCath.Cash and short-term investments, excluding restricted cash, at September 30, 2024 amounted to $46.0 million. Joe Todisco, CorMedix CEO, commented, “I am excited about the Company’s recent progress as we execute on our launch objectives and increase patient access to DefenCath across settings of care. Having established patient access at roughly 60% of outpatient dialysis clinics in the US, I’m optimistic about the opportunity for DefenCath as we shift focus toward 2025. We have several important clinical initiatives commencing early next year aimed at expanding indications for DefenCath beyond adult hemodialysis, providing an important catalyst for future growth.” Third Quarter and Nine Months 2024 Financial Highlights For the third quarter of 2024, CorMedix recorded $11.5 million in net revenue from sales of DefenCath for the first full quarter sales since DefenCath was launched in 2024. For the third quarter of 2024, CorMedix recorded a net loss of $2.8 million, or $0.05 per share, compared with a net loss of $9.7 million, or $0.17 per share, in the third quarter of 2023, a decrease of $6.9 million or 72%. The decrease in net loss was driven primarily by the launch of DefenCath and net sales in the period. Operating expenses in the third quarter 2024 were $14.1 million, compared with $10.5 million in the third quarter of 2023, an increase of approximately 34%. The increase was driven by higher selling and marketing (S&M) and general and administrative (G&A) expenses which increased approximately 66% and 76%, respectively. These increases were partially offset by a decrease in research and development (R&D) expenses of approximately 73%. The increases in S&M and G&A were primarily driven by increased marketing efforts and the hiring of sales force, medical affairs and marketing personnel in support of the commercial launch of DefenCath. Additionally, as a result of the post FDA approval commercial operations, costs related to medical affairs and certain personnel expenses that supported R&D efforts prior to the FDA approval of DefenCath have been recognized primarily in G&A expense during the three months ended September 30, 2024. For the nine months ended September 30, 2024, CorMedix recorded a net loss of $31.4 million, or $0.54 per share, compared with a net loss of $31.6 million, or $0.65 per share, in the same period in 2023, a decrease of $0.2 million, or 0.6%, driven primarily by $12.3 million in net revenue and proceeds received from the sale of our unused New Jersey net operating losses, offset by an increase in operating expenses. Operating expenses in the first nine months of 2024 were $45.5 million, compared to $33.3 million during the comparative period in 2023, an increase of approximately 37%. This increase was primarily due to costs related to marketing and commercial activities in support of the launch activities of DefenCath, partially offset by a decrease in R&D expenses, attributable to the marketing approval of DefenCath. The Company reported cash and short-term investments of $46.0 million as of September 30, 2024, excluding restricted cash. The Company believes that it has sufficient resources to fund operations for at least twelve months from the issuance of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. Conference Call Information The management team of CorMedix will host a conference call and webcast today, October 30, 2024, at 8:30AM Eastern Time, to discuss recent corporate developments and financial results. Call details and dial-in information are as follows: Wednesday, October 30th @ 8:30am ET Domestic: International:Webcast: 1-844-481-25571-412-317-0561Webcast Link About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “will,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, and readers are directed to the Risk Factors identified in CorMedix’s filings with the SEC, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of this press release. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law. Investor Contact:Dan FerryManaging DirectorLifeSci Advisorsdaniel@lifesciadvisors.com(617) 430-7576 CORMEDIX INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(Unaudited) For the Three Months Ended September 30, For the Nine Months Ended September 30, 2024 2023 2024 2023 Revenue Revenue, net$11,456,115 $- $12,262,234 $- Cost of revenues (686,598) - (2,014,975) - Gross profit (loss) 10,769,517 - 10,247,259 - Operating Expenses Research and development (727,119) (2,663,976) (2,215,551) (10,866,236)Selling and marketing (6,748,900) (4,058,428) (20,472,961) (9,955,651)General and administrative (6,580,834) (3,744,879) (22,851,144) (12,467,157)Total operating expenses (14,056,853) (10,467,283) (45,539,656) (33,289,044)Loss from Operations (3,287,336) (10,467,283) (35,292,397) (33,289,044)Other Income (Expense) Total other income 510,524 722,929 2,503,203 1,703,846 Net Loss Before Income Taxes (2,776,812) (9,744,354) (32,789,194) (31,585,198)Tax benefit - - 1,394,770 - Net Loss (2,776,812) (9,744,354) (31,394,424) (31,585,198)Other Comprehensive Income (Loss) Total other comprehensive income (loss) 3,389 (6,298) (4,988) 1,656 Other Comprehensive (Loss) Income$(2,773,423)$(9,750,652)$(31,399,412)$(31,583,542)Net Loss Per Common Share – Basic and Diluted $(0.05)$(0.17)$(0.54)$(0.65)Weighted Average Common Shares Outstanding – Basic and Diluted 58,825,221 56,553,174 57,986,190 48,715,585 CORMEDIX INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEET DATA September 30, 2024 December 31, 2023 (Unaudited) (Audited) ASSETS Cash, cash equivalents and restricted cash$35,391,222 $43,823,192 Short-term investments$10,743,562 $32,388,130 Total Assets $77,586,194 $82,059,957 Total Liabilities $18,873,926 $11,917,528 Accumulated deficit$(353,094,437)$(321,700,013) Total Stockholders’ Equity $58,712,268 $70,142,429 CORMEDIX INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited) For the Nine Months Ended September 30, 2024 2023 Cash Flows from Operating Activities: Net loss$(31,394,424) $(31,585,198)Net cash used in operating activities (45,000,117) (27,663,786)Cash Flows Used in Investing Activities: Net cash provided by (used in) investing activities 21,534,874 (17,659,477)Cash Flows from Financing Activities: Net cash provided by financing activities 15,033,751 55,449,154 Net (Decrease) Increase in Cash and Cash Equivalents (8,431,970) 10,126,276 Cash and Cash Equivalents and Restricted Cash - Beginning of Period 43,823,192 43,374,745 Cash and Cash Equivalents and Restricted Cash - End of Period$ 35,391,222 $ 53,501,021

Drug ApprovalFinancial Statement

24 Oct 2024

·www.globenewswire.com

CorMedix Inc. Announces New Data at ASN Kidney Week 2024

Study highlights significant healthcare challenges and costs associated with bloodstream infections (BSIs) in patients receiving chronic hemodialysis through central venous catheters (HD-CVCs)BERKELEY HEIGHTS, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced new hospital admission and health economic data presented at the American Society of Nephrology Kidney Week 2024 in San Diego, CA from October 24 - 27. This retrospective analysis, using data from the Premier Healthcare Database, evaluated hospital admissions from 2020 to 2022 to examine the demographics, clinical characteristics, and outcomes of adult HD-CVC patients hospitalized for bloodstream infections (BSIs). Among the 91,448 unique patients admitted, 25% (N=22,902) presented with a BSI. Key findings include: Patient Demographics: The patient population was 58.2% white, 27.1% black, and 56.6% male, with 59.3% aged 60 years or older. A substantial number of patients lived in vulnerable communities, with 47% residing in the most socioeconomically disadvantaged quartile of neighborhoods nationwide.Hospitalization Outcomes: The median length of stay for BSI-related hospitalizations was 16 days, with 53.8% of admissions involving time in the ICU (median stay: 8 days). The study reported an all-cause in-hospital mortality rate of 10.3%.Comorbidities: Patients had extensive comorbidities, with 87.8% having three or more Charlson comorbidity conditions, and 42.6% had six or more.Economic Impact: The median total cost of admission was $157,000, with $65,000 attributed to ICU care alone. Healthcare utilization, including readmissions (26.8% within 90 days), placed a significant financial burden resulting from these infections. "This study underscores the critical need for improved prevention strategies and interventions in the management of catheter-related bloodstream infections (CRBSIs) among hemodialysis patients," says CorMedix CEO, Joseph Todisco. "With one in four patients admitted for a bloodstream infection and a 10% in-hospital mortality, along with median hospitalization costs of $157,000, reducing both the incidence and financial impact of these infections is critical." This poster presentation will be made available on the Company’s website at www.cormedix.com/publications-and-presentations. About CorMedixCorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin), which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com. Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “will,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, and readers are directed to the Risk Factors identified in CorMedix’s filings with the SEC, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of this press release. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law. Investor Contact:Dan FerryManaging DirectorLifeSci Advisorsdaniel@lifesciadvisors.com(617) 430-7576

Drug ApprovalClinical Result

23 Oct 2024

·www.prnewswire.com

The Human Platelet Lysate market is projected to grow by USD 0.011 Million from 2024-2028, driven by AI and the rising prevalence of chronic diseases - Technavio

NEW YORK, Oct. 23, 2024 /PRNewswire/ -- Report on how AI is driving market transformation - The Global Human Platelet Lysate Market size is estimated to grow by USD 0.011 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 3.64% during the forecast period. Rising prevalence of chronic diseases is driving market growth, with a trend towards growing investments in stem cell research. However, stringent regulations and quality control requirements for human-derived products poses a challenge - Key market players include Amerigo Scientific, AventaCell BioMedical Corp. Ltd., BioLife Solutions Inc., Compass Biomedical Inc., Creative Biolabs, GeminiBio, Macopharma SA, Merck KGaA, Mill Creek Life Sciences Inc., MP Biomedicals Inc., PAN-Biotech GmbH, PL BioScience GmbH, Regenexx Des Moines, Sartorius AG, Sartorius CellGenix GmbH, Serana Europe GmbH, STEMCELL Technologies Inc., TCS Biosciences Ltd., TRINOVA BIOCHEM GmbH, and ZenBio Inc.. Continue Reading Technavio has announced its latest market research report titled Global human platelet lysate market 2024-2028 Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View the snapshot of this report Market Driver The human platelet lysate market is experiencing significant growth due to increasing investments in stem cell research. Stem cells, with their potential to treat various diseases, necessitate high-quality cell culture supplements for growth and differentiation. Human platelet lysate, abundant in growth factors and cytokines, is a preferred choice in this field due to its compatibility with human cells and efficient cell proliferation properties. For instance, the California Institute for Regenerative Medicine (CIRM) recently approved an USD89 million investment for stem cell and gene therapy research, with nearly USD39 million allocated to four projects in CIRM's Clinical program. As stem cell and gene therapy advance, the demand for human platelet lysate will increase, driven by its crucial role in cell culture and regenerative medicine. Consequently, the global human platelet lysate market is expected to witness substantial growth during the forecast period, fueled by continued investments from governments, academic institutions, and biopharmaceutical companies in stem cell research. The Human Platelet Lysate market is experiencing significant growth due to increasing trends in personalized treatment solutions. This innovative biomedical product derived from human blood platelets is gaining popularity in various industries, including orthopedics and dermatology. Animal-derived supplements are being replaced with high-quality human platelet lysate for osteoarthritis treatment and cartilage regeneration. Key players in this market include cutting-edge innovators, providing active ingredients for therapeutic applications. Manufacturing obstacles and safety regulations are being addressed with efficient cell culture techniques and safety measures. Ethical considerations and contagious diseases are also prioritized, ensuring the highest standards. Applications extend to hair regrowth treatments in clinics and cytokines for neurodegenerative disorders like Parkinson's Disease and stem cell research. With a tailored strategy, regulatory landscape, and focus on safety and efficiency, the human platelet lysate market is poised for continued growth in the realm of regenerative medicine and tissue engineering. Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution! Market Challenges The human platelet lysate market faces substantial regulatory challenges, impacting product development and commercialization. Regulatory bodies like the FDA in the US and EMA in Europe impose rigorous requirements on human-derived product collection, processing, and testing to ensure safety and efficacy. These stringent regulations add to the cost and complexity of bringing products to market. Moreover, varying requirements in different countries can complicate global market entry. Companies must also maintain consistent product quality and adhere to safety protocols, such as those outlined in the ICH guidelines. Keeping up with evolving regulations and guidelines is essential. Overall, these regulatory hurdles pose a significant challenge to the growth of the global human platelet lysate market. The Human Platelet Lysate (HPL) market is witnessing significant growth due to its increasing applications in various clinical fields. One of the major challenges in this market is the shift towards Heparin-Free HPL, which is gaining popularity due to its compatibility with stem cell therapy and clinical trials. Heparin, a common anticoagulant used in traditional HPL, can negatively impact cell performance and reproducible results. Moreover, the market is witnessing an increasing focus on innovative treatments for chronic diseases such as cancer therapy and wound healing. Biotechnology companies are investing in the development of standardized, safe, and effective HPL for clinical applications. Pharmaceutical and healthcare facilities are exploring patent license agreements to manufacture and distribute HPL for various disease indications. Biogelx, a leading stem cell platform, is at the forefront of this trend, offering HPL for cell culture systems and tissue repair. HPL is rich in platelet-derived growth factors, which play a crucial role in cellular proliferation, angiogenesis, fibroblast proliferation, and extracellular matrix production. The market is also witnessing an increasing focus on the use of HPL in infectious diseases, drug discovery, and cell-based therapeutics. In conclusion, the Human Platelet Lysate market is a dynamic and growing industry, driven by the need for safe, effective, and reproducible results in various clinical applications, including stem cell therapy, clinical trials, chronic diseases, and tissue repair. Companies that can offer standardized and safe HPL are well-positioned to capitalize on this trend. Discover how AI is revolutionizing market trends- Get your access now! Segment Overview This human platelet lysate market report extensively covers market segmentation by Type 1.1 Heparin free human platelet lysate 1.2 Human platelet lysate with heparin Application 2.1 Research use 2.2 Clinical use Geography 3.1 North America 3.2 Europe 3.3 Asia 3.4 Rest of World (ROW) 1.1 Heparin free human platelet lysate- The Human Platelet Lysate market is experiencing significant growth due to its increasing usage in various research applications, particularly in biotechnology and pharmaceuticals. This market is driven by the rising demand for advanced diagnostic tools and therapeutic treatments. Key players in this market include Thermo Fisher Scientific, Sigma-Aldrich, and Gibco. These companies provide high-quality human platelet lysate products to meet the growing demand from researchers and healthcare professionals. Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics Research Analysis The Human Platelet Lysate (HPL) market is a significant segment of the biomedical industry, playing a crucial role in regenerative medicine, cell culture techniques, and therapeutic applications. HPL is derived from human platelets and contains various cytokines, growth factors, and other bioactive molecules that promote cellular proliferation, differentiation, and healing. HPL is used extensively in stem cell research, tissue engineering, and cell therapy for chronic diseases such as Parkinson's disease, neurodegenerative disorders, and injuries. Safety and efficiency are paramount in the production of HPL, with ethical considerations also being a significant factor. Fetal bovine serum (FBS) has traditionally been used as a supplement in cell culture, but HPL offers several advantages, including standardized, safe, and reproducible results. HPL is also heparin-free, making it an attractive alternative for pharmaceutical and healthcare facilities. The regulatory landscape for HPL is evolving, with clinical trials underway for various applications, including cancer therapy, wound healing, and infectious diseases. Innovative treatments using HPL are being explored in biotechnology, and the market is expected to grow significantly in the coming years due to its clinical applications in chronic diseases and therapeutic uses. Biogelx, for instance, is a leading provider of HPL for research and therapeutic applications, offering high-quality and consistent products for cell performance and differential potential. Market Research Overview The Human Platelet Lysate (HPL) market is a significant segment in the biomedical industry, playing a crucial role in regenerative medicine, cell culture techniques, and therapeutic applications. HPL is derived from platelets, which contain various bioactive compounds such as cytokines, platelet-derived growth factors, and other growth factors that promote cellular proliferation, angiogenesis, fibroblast proliferation, and extracellular matrix production. HPL is used in various clinical applications, including stem cell therapy for neurodegenerative disorders like Parkinson's disease, chronic diseases, and innovative treatments for infectious diseases. The regulatory landscape for HPL is stringent due to safety considerations, and manufacturers must adhere to ethical guidelines and quality standards. HPL is used in biotechnology and pharmaceutical industries for drug discovery and cell-based therapeutics, as well as in healthcare facilities for wound healing, cancer therapy, and tissue repair. The market for HPL is growing due to the increasing demand for high-quality solutions for personalized treatment and the development of heparin-free HPL and innovative cell culture systems. However, manufacturing obstacles and safety regulations pose challenges to the market's growth. Overall, the HPL market is a cutting-edge and active area of research, with potential applications in various industries and clinical indications. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation Type Heparin Free Human Platelet Lysate Human Platelet Lysate With Heparin Application Research Use Clinical Use Geography North America Europe Asia Rest Of World (ROW) 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Cell Therapy

100 Deals associated with Heparin Calcium

External Link

KEGG	Wiki	ATC	Drug Bank
D04427	Heparin Calcium	S01XA14 B01AB01 C05BA03	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Disease, Chronic Obstructive	Phase 2	GB	Ockham Biotech Ltd.	30 Jan 2022
Cystic Fibrosis	Phase 1	GB	Ockham Biotech Ltd.	30 Jan 2022
Asthma	Preclinical	GB	Ockham Biotech Ltd.	30 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


PERIOP-01 (ASH2023)	Not Applicable	Colorectal Cancer	614	Extended duration thromboprophylaxis with low-molecular-weight-heparin	dtefzxgwaz(vxbdzbiyek) = kunvrbmxui kegxbvojup (zutdfcvgns ) View more	-	10 Dec 2023
				Standard duration thromboprophylaxis	dtefzxgwaz(vxbdzbiyek) = isqrxpzsgg kegxbvojup (zutdfcvgns ) View more
ESC2023	Not Applicable	-	768	Heparin dose 50IU/kg	pdswbcivuo(smlyrhgonr) = laddbudims vwbamdcmzt (frnnyowusj )	-	27 Aug 2023
				Heparin dose ≥70IU/kg	pdswbcivuo(smlyrhgonr) = kmkuidkuvg vwbamdcmzt (frnnyowusj )
NCT03894904 (CTgov)	Phase 4	Anesthesia \| Vasospasm	100	Heparin+Papaverine (Papaverine Plus Heparin During Procedure, With Rescue Papaverine as Needed)	xzbdshedyw(vyebkgllmj) = vjiduljllg fwyzwlklhy (bxttwdpuzy, ounrfjutyd - wxgabvrydo) View more	-	27 Oct 2022
				Heparin+Rescue papaverine, as needed (Heparin During Procedure, With Rescue Papaverine as Needed)	xzbdshedyw(vyebkgllmj) = mgkohfgmyq fwyzwlklhy (bxttwdpuzy, czkatbjgxl - dguvvshxlp) View more
Highlow Study (ISTH2022)	Not Applicable	Venous Thromboembolism D-dimer \| PAP \| von Willebrand factor (vWF) ... View more	217	Intermediate-dose low-molecular-weight heparin	aoezsvusih(tdouczhdsr) = zexpnjrdzf ogyrzfbgpd (khpeupntlg )	-	09 Jul 2022
				Low-dose low-molecular-weight heparin	aoezsvusih(tdouczhdsr) = iejmxlaofb ogyrzfbgpd (khpeupntlg )
ISTH2022	Not Applicable	COVID-19	-	Standard-dose heparin prophylaxis	msyvjvwyyz(qmrkvigwty) = zcxdrieidh sppfkxhuws (looolijfjr ) View more	-	09 Jul 2022
				High-dose heparin prophylaxis	msyvjvwyyz(qmrkvigwty) = editguognq sppfkxhuws (looolijfjr ) View more
Pubmed \| Cancer Nurs	Not Applicable	Acute Lymphoblastic Leukemia	61	Heparin (Normal saline)	iydqrysnfp(wxlveddecf) = Adverse events did not differ between groups rczdxgvnog (deyhnnbgmp )	-	05 Feb 2022
ESC2021	Not Applicable	COVID-19	-	Prophylactic dose of heparin	-	Positive	29 Aug 2021
				Therapeutic dose of heparin
ESC2021	Not Applicable	COVID-19 respiratory infection	3,458	Standard prophylactic heparin doses	nfeicnxkyy(enaexcjfit): RR = 1.06 (95% CI, 0.58 - 1.95) View more	-	27 Aug 2021
				Higher heparin doses
ISTH2021	Not Applicable	Complications of bariatric procedures	-	Weight-adjusted LMWH regimens	qqqdkpkkng(jwhjdrdepn) = hbnqqukhvz uxqliiilko (oaroaptyaa ) View more	-	17 Jul 2021
				Non-weight adjusted LMWH regimens	qqqdkpkkng(jwhjdrdepn) = vccblzrteq uxqliiilko (oaroaptyaa ) View more
ERA2021	Not Applicable	Infection of hemodialysis catheter	-	Sodium Heparin Lock Solution	bwutplatuy(pmhirebzsp) = slightly lower on Bic-lock phase akckdqdygn (otdbqvknue ) View more	-	29 May 2021
				Sodium Bicarbonate Lock Solution

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Heparin Calcium

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation